VAFP
JSPR icon

Vahanian & Associates Financial Planning’s Jasper Therapeutics JSPR Stock Holding History

Vahanian & Associates Financial Planning’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,000
Closed -$36K – 51
2022
Q1 		$36K Sell
1,000
-1,500
-60% -$67.6K 0.08% 60
2021
Q4 		$196K Buy
+2,500
New +$234K 0.16% 151

Other funds holding JSPR

QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FA
Forefront Analytics West Conshohocken, Pennsylvania $110M AUM 18.54% 1-Year Est. Return

Vahanian & Associates Financial Planning's JSPR Position: Q2 2022 in Review

Vahanian & Associates Financial Planning sold out of Jasper Therapeutics (JSPR) in Q2 2022, closing a stake of 1,000 shares — an estimated $36K sold.

Vahanian & Associates Financial Planning first reported a position in JSPR in Q4 2021 and held it in 2 quarters. The position peaked at $196K in Q4 2021. 23 funds tracked by Wall St. Rank hold JSPR as of Q2 2022.

  • Vahanian & Associates Financial Planning reported no remaining Jasper Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Vahanian & Associates Financial Planning sold 1,000 Jasper Therapeutics shares in Q2 2022, an estimated $36K.
  • Vahanian & Associates Financial Planning first reported a position in Jasper Therapeutics in Q4 2021 and held it in 2 quarters.
  • Vahanian & Associates Financial Planning's Jasper Therapeutics position peaked at $196K in Q4 2021.
  • 23 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2022.

Based on Vahanian & Associates Financial Planning's 13F filing for Q2 2022, filed 27 Jul 2022.